KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Shares Outstanding (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 14 years of Shares Outstanding data on record, last reported at -$19.9 million in Q1 2022.

  • For Q1 2022, Shares Outstanding fell 1205.56% year-over-year to -$19.9 million; the TTM value through Mar 2022 reached -$19.9 million, down 1205.56%, while the annual FY2020 figure was -$16.4 million, 234.69% down from the prior year.
  • Shares Outstanding reached $127.6 million in Q1 2022 per REGN's latest filing, up from $1.8 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $127.6 million in Q1 2022 and bottomed at -$15.7 million in Q3 2020.
  • Average Shares Outstanding over 5 years is $21.0 million, with a median of $1.8 million recorded in 2020.
  • Peak YoY movement for Shares Outstanding: skyrocketed 145.0% in 2020, then crashed 1205.56% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $1.9 million in 2018, then plummeted by 357.89% to -$4.9 million in 2019, then tumbled by 234.69% to -$16.4 million in 2020, then surged by 110.98% to $1.8 million in 2021, then plummeted by 1205.56% to -$19.9 million in 2022.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were -$19.9 million in Q1 2022, $1.8 million in Q3 2021, and -$17.7 million in Q2 2021.